



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

# Hypertension and Acromegaly

This is a pre print version of the following article:				
Original Citation:				
Availability:				
This version is available http://hdl.handle.net/2318/1719505since 2022-10-12T09:22:12Z				
Published version:				
DOI:10.1016/j.ecl.2019.08.008				
Terms of use:				
Open Access				
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.				

(Article begins on next page)

# 1 HYPERTENSION AND ACROMEGALY

2	Soraya	Puglisi	<sup>1</sup> , Massimo	Terzolo <sup>1</sup> .
---	--------	---------	------------------------	------------------------

3	<sup>1</sup> Internal Medicine 1, Department of Clinical and Biological Sciences, University of Turin, Italy;					
4						
5	Soraya Puglisi					
6	Internal Medicine 1, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital,					
7	Regione Gonzole 10, 10043 Orbassano, Italy; tel: +39 011 9026292, fax: +39 011 6705456					
8	e-mail: sorayapuglisi@yahoo.it					
9						
10	Corresponding Author: Massimo Terzolo					
11	Internal Medicine 1, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital,					
12	Regione Gonzole 10, 10043 Orbassano, Italy; tel: +39 011 9026292, fax: +39 011 6705456					
13	e-mail: terzolo@usa.net					
14						
15						
15						
16	Declaration of interest					
17	Soraya Puglisi has stated explicitly that there are no conflicts of interest in connection with this					
18	article.					
19	Massimo Terzolo has received research grants from Novartis.					
20						
21						
22	KEY WORDS: blood pressure, cardiovascular risk, anti-hypertensive treatment, cardiovascular					

23 complication, mortality, prevalence, pathogenesis, sleep apnea.

#### 24 **KEY POINTS:**

25 Hypertension is one of the most important and common complications in acromegaly, • 26 responsible to increased cardiovascular risk, higher rate of hospitalization and greater costs 27 for the disease management. 28 The pathogenesis has not yet been fully elucidated and likely includes multiple factors. ٠ 29 A comprehensive, patient-centered approach, focusing not only on the biochemical control • 30 of acromegaly, but also on an early diagnosis of hypertension and a prompt anti-31 hypertensive treatment, is required for optimal patient care. 32 33 34 **SYNOPSIS** 35 Hypertension is one of the most frequent complications in acromegaly, with a median frequency of 36 33.6% (ranging from 11 to 54.7%). Although the pathogenesis has not been fully elucidated, it is 37 probably the result of concomitant factors leading to expansion of extracellular fluid volume, 38 increase of peripheral vascular resistances and development of sleep apnea syndrome. As the effect 39 of normalization of GH and IGF1 excess on blood pressure levels is unclear, an early diagnosis of 40 hypertension and prompt anti-hypertensive treatment are eagerly recommended, regardless of the 41 specific treatment of the acromegalic disease and the level of biochemical control attained.

#### 42 INTRODUCTION

43 Acromegaly is a rare, chronic disease whose clinical manifestations are the consequence of GH and IGF1 excess that is usually caused by a GH-secreting pituitary adenoma<sup>1</sup>. The disease is associated 44 with a significant number of complications and comorbid conditions, mainly affecting the 45 cardiovascular (CV) system<sup>2</sup>. Arterial hypertension is among the most frequent CV complications 46 of acromegaly; however, its role as a prognostic factor is not definitely established <sup>3-7</sup>, despite the 47 negative impact of hypertension on the acromegalic cardiomiopathy <sup>8,9</sup>. The classic view that CV 48 disease is the main culprit for the excess mortality in acromegalic patients <sup>2,4</sup> has been revisited in 49 more recent studies <sup>6,10,11</sup>. Nevertheless, CV disease is associated with an important disease burden, 50 and significantly increases the rate of hospitalization and the health care costs <sup>12</sup>. 51

52

#### 53 PREVALENCE AND CHARACTERISTICS

The frequency of hypertension in acromegaly varies from 11% to 54.7%, averaging 33.6%, as 54 reported in Table 1 that includes the main studies published in the last 15 years <sup>3,4,6</sup> <sup>13-23</sup>. The 55 56 variability found in the prevalence of hypertension could be attributed to the different diagnostic criteria adopted over different periods of recruitment, and to population-related risk factors (genetic 57 58 and racial differences, prevalence of obesity, unhealthy life style, such as smoking and excessive 59 sodium or alcohol intake). It is worth of note that all these studies were retrospective and reported 60 only on office measurements of blood pressure (BP), likely overestimating the actual frequency of 61 hypertension compared with the ambulatory blood pressure monitoring (ABPM).

This caveat was first demonstrated by Minniti et al. <sup>24</sup>, who reported a frequency of 42.5% of hypertension in acromegalic patients with office BP measurements versus a frequency of 17.5% with ABPM. Similar findings were recently found by Costenaro et al. <sup>25</sup>, who demonstrated a rate of 23% hypertension with ABPM versus 32% with clinical measurements. Interestingly, they reported that BP levels recorded by ABPM were correlated with GH and IGF1 concentrations.

The correlation between severity of hypertension and GH, or IGF1 levels, has been investigated in 67 several studies, but findings are discordant <sup>6,26,27</sup>. A recent paper tried to dissect the problem, 68 69 showing a positive correlation between BP levels and IGF1 concentrations when the latter were 70 above the upper limit of normalcy, with an inverse relationship when IGF1 levels were within the normal range <sup>28</sup>. The analysis included several studies, most of which have been carried out in non-71 72 acromegalic patients, and supports a direct relationship in states characterized by overtly elevated 73 IGF1, like uncontrolled acromegaly. In addition, it is plausible that other variables are important determinants of hypertension in acromegaly, such as the duration of disease <sup>27, 29</sup>, patient age and 74 body mass index, while family history of hypertension or gender have a more controversial role <sup>19</sup>, 75 27, 30 76

Hypertension in acromegalic patients is generally regarded as a mild disease that can be easily managed with standard antihypertensive drugs <sup>31</sup>. A peculiar pattern of acromegaly-associated hypertension may be found in higher diastolic BP and lower systolic BP levels compared to nonacromegalic hypertensive subjects <sup>27, 32</sup>. Furthermore, studies using ABPM found a higher prevalence of non-dippers (almost 50%) in acromegalic hypertensive patients compared with patients with primary hypertension <sup>32, 33</sup>. The non-dipping pattern is shared with other types of secondary hypertension and is associated with increased CV morbidity and mortality.

84

85

#### 86 **PATHOGENESIS**

The pathogenesis of hypertension in acromegaly has not been yet fully clarified, but a multifactorial origin is the most convincing explanation (**Figure 1**). The development of hypertension may be attributable to a combined effect of a chronic GH/IGF1 excess on different systems that finally causes expansion of extracellular fluid volume, increase of peripheral vascular resistances, and development of the sleep apnea syndrome.

### 93 EXPANSION OF EXTRACELLULAR FLUID VOLUME

94 The increase of total extracellular fluid volume is secondary to sodium and water retention by the
95 kidney, due to direct and indirect effects of GH/IGF1<sup>34</sup>.

96

## 97 *a) Direct GH anti-natriuretic effects*

98 The hypothesis of a GH direct effect fits well with the demonstration of GH receptors in human adrenal cortex <sup>35</sup>. In rat models of acromegaly, GH had an aldosterone-independent anti-natriuretic 99 effect, mediated through the epithelial Na<sup>+</sup> channels (ENaC) of collecting ducts <sup>36</sup>. The rats received 100 101 furosemide, an antidiuretic drug able to inhibit the sodium reabsorption NCCK2 channels in the 102 loop of Henle, and amiloride, which blocks the ENaC channels in the collecting ducts. In 103 acromegalic rats, the furosemide-induced natriuresis was lower compared to controls, whereas the 104 amiloride-induced natriuresis was higher, confirming the hypothesis that GH stimulates sodium 105 transport in the distal nephron via ENaC channels. The increased activity of ENaC channels in 106 acromegaly was demonstrated also in humans, using a similar model of pharmacological challenge 107 with amiloride and furosemide <sup>37</sup>.

108

# 109 b) Effects of GH on the renin-angiotensin-aldosterone system

The relationship between the renin-angiotensin-aldosterone system (RAAS) and GH/IGF1 excess has been carefully evaluated in the last decades, but remains controversial. The leading hypothesis is that increased aldosterone levels, directly stimulated by GH excess, contribute to hypertension in acromegaly without stimulation of plasma renin activity (PRA) <sup>38</sup>. As matter of fact, no change has been found in RAAS activity during IGF1 administration <sup>39</sup> and low levels of PRA have been consistently detected in acromegalic patients <sup>40, 41</sup>.

116 A significant direct correlation between GH and aldosterone values in acromegalic patients has 117 been observed and serum aldosterone concentration significantly decreased after normalization of 118 GH secretion due to surgical cure, whereas renin concentrations remained unaffected. In animal 119 models, the association of chronic GH excess with increased aldosterone was independent of renin, IGF-I, or adrenal aldosterone synthase expression <sup>38</sup>. On the contrary, a study concerning the 120 polymorphisms of genes involved in the RAAS has underlined the role of aldosterone synthase 121 122 (CYP11B2), showing that acromegalic patients with the CYP11B2 - 344CC genotype were affected by hypertension more frequently than patients with the CT/TT genotypes, with a significant 123 increase of systolic BP<sup>42</sup>. Conversely, no significant effect of polymorphisms in other genes, such 124 as angiotensinogen (AGT) or angiotensin-converting enzyme (ACE), was reported in agreement 125 126 with the findings of a more recent study  $^{43}$ .

127

# 128 c) IGF1-mediated inhibition of ANP

Some studies showed a reduction of atrial natriuretic peptide (ANP) secretion in acromegalic 129 patients. McKnight and colleagues <sup>44</sup> compared plasma ANP levels of patients with active 130 131 acromegaly versus healthy subjects, before and after a 4-h intravenous infusion of normal saline. 132 ANP levels rose significantly in the control group, whereas in acromegalic patients they did not 133 respond to saline stimulation. Although the basal ANP values were similar between the two groups, the 4-h ANP levels were significantly higher in the group of healthy subjects than in the 134 acromegalic group. A few years later, Moller et al. <sup>39</sup> demonstrated that the inhibition of ANP-135 136 induced natriuresis is mediated by IGF-I.

137

### 138 *d) Insulin mediated effect*

139 It is well known that acromegaly is often associated with insulin resistance and hyperinsulinemia. 140 The anti-natriuretic effect of insulin has long been debated, but an action on renal sodium 141 absorption has confirmed <sup>45</sup>. Although experimental studies in acromegalic patients are not 142 available, the pathophysiological role of insulin-mediated changes in sodium balance fits well with 143 the finding of higher insulin levels after oral glucose tolerance load in hypertensive than 144 normotensives acromegalic patients <sup>46</sup>, and higher BP levels in hyperinsulinemic acromegalic patients <sup>47</sup>. On the other hand, other studies did not find a difference in fasting or post-load plasma insulin values between hypertensive and normotensives acromegalic patients <sup>48, 49</sup>, suggesting that other factors could be involved in the pathogenesis, such as the insulin-mediated activation of the sympathetic nervous system <sup>50, 51</sup>.

149

### 150 e) Sympathetic nervous system mediated effect

The influence of the sympathetic nervous system on tubular processing of sodium is well known <sup>51</sup>. On the contrary, controversial data on the role of an impaired sympathetic tone in acromegaly have been reported in the last decades <sup>50</sup>. In this area of debate, the assessment of the 24-hour profiles of plasma catecholamine levels and BP in 14 acromegalic patients (before and after pituitary surgery) and 8 healthy controls demonstrated a flattened 24-hour profile of norepinephrine and BP in acromegalic patients, while the circadian norepinephrine rhythm was restored after surgery with normalization/reduction of GH/IGF-I levels <sup>52</sup>.

158

# 159 INCREASE OF PERIPHERAL VASCULAR RESISTANCES

The effect of chronic GH and IGF-I excess on vascular resistances could explain the more apparent increase of diastolic versus systolic BP in acromegalic patients <sup>27, 32</sup>. Recently, a study assessed with renal ultrasonography 57 acromegalic patients and showed that the Renal Resistive Index (RRI) was higher in 16 hypertensive acromegalic patients compared to 49 normotensive patients <sup>53</sup>. Moreover, the RRI value was independently related to the presence of hypertension and correlated with IGF-1 levels, supporting the hypothesis of a link between the severity of acromegaly and hypertension.

166

# 167 a) Stimulation of vascular RAAS and vascular hypertrophy

168 It has been demonstrated *in vitro* that both IGF1 and insulin were able to stimulate angiotensinogen 169 production in cultures of vascular smooth muscle cells <sup>54</sup>. Interestingly, the same study showed the 170 role of the two hormones in the development of vascular hypertrophy, through activation of the 171 vascular RAAS. It is conceivable that the same mechanism could play a role in the pathogenesis of 172 hypertension in acromegaly, according to studies that demonstrated an association between hyperinsulinemia and hypertension in this group of patients <sup>46, 47</sup>. This hypothesis suits well with 173 evidence of a hypertrophic remodeling of subcutaneous small resistance arteries in acromegalic 174 patients compared with the eutrophic remodeling in patients with essential hypertension <sup>55</sup>. The 175 176 assessment of the structure of small arteries in biopsies of subcutaneous fat and of the calculated 177 media-to-lumen ratio and growth indices demonstrated the effect of growth factors in the 178 development of vascular morphological alterations. A weak, but statistically significant correlation 179 between the media-to-lumen ratio and IGF-1 values was also found in this small group of 9 180 acromegalic patients. Similar findings on vascular hypertrophy in acromegaly, and a positive 181 association between wall thickness and IGF-I levels, have been showed in a subsequent study including a larger sample of 41 patients  $^{56}$ . 182

183

### 184 b) Endothelial dysfunction

185 The comparison of the cutaneous vasoreactivity responses of 10 normotensive acromegalic patients with 10 healthy controls demonstrated in the former group an impaired endothelium-dependent 186 vasodilatation, which is mediated by nitric oxide (NO)<sup>57</sup>. The NO pathway has been subsequently 187 188 evaluated, also taking in consideration its effects on vascular resistance, platelet aggregation and 189 inhibition of smooth muscle cell proliferation. A few years later, it was demonstrated a decrease of 190 NO concentrations in acromegalic patients, due to a reduced endothelial NO synthase expression, and an inverse correlation between NO and GH/IGF-1 levels, and duration of acromegaly <sup>58</sup>. 191 Several recent studies confirmed the impairment of flow-mediated vasodilation <sup>59, 60</sup> and the role of 192 reduced NO levels in acromegaly <sup>56, 61</sup>, which may contribute to both hypertension and erectile 193 dysfunction in male acromegalic patients <sup>62</sup>. Finally, it deserves to be mentioned also the 194 association between endothelial dysfunction and insulin resistance <sup>63</sup>, as a further possible 195 196 mechanism in this complex scenario.

197

## 198 c) Sympathetic activation

199 The evidence of an over-reactivity to sympathetic stimulation in acromegaly has been provided using a cold pressor test to study sympathetic vasoreactivity 57. The study showed a significantly 200 201 more pronounced increase in systolic BP, and a trend to a greater decrease in skin perfusion, in 202 acromegalic patients compared with healthy control, with a greater, although not statistically 203 significant, vasoconstriction in acromegaly. On the other hand, there are few and contradictory data 204 on catecholamine levels without any clear evidence of increased sympathetic tone in acromegalic patients <sup>50</sup>. A study comparing acromegalic patients and hypertensive control reported a 24-hour 205 206 catecholamine secretion that was quantitatively similar, but without any circadian rhythm and a normal fall during the night in acromegalic patients <sup>52</sup>. This is in agreement with other findings 207 208 indicating a reduced nocturnal fall in BP in both normotensive and hypertensive acromegalic 209 patients, with a prevalence of the "non-dipper" profile (mean nocturnal BP  $\leq 10\%$  of the average davtime BP) <sup>32, 64</sup>. 210

211

#### 212 SLEEP APNEA

213 Sleep apnea syndrome (SAS) is common in acromegaly, mainly due to anatomical changes in the entire respiratory system<sup>29</sup>. Particularly, alterations of the bone and soft tissues in the craniofacial 214 215 region (mandibular prognathism due to growth effect of GH/IGF1, macroglossia, pharyngeal and 216 laryngeal swelling due to sodium and water retention) reduce the airflow during sleep, causing repeated hypoxic and hypercapnic episodes <sup>65</sup>. Therefore, the prevalence of SAS in active 217 acromegaly is up to 45-80% of patients, according to different studies <sup>66</sup>. As in the general 218 population, SAS is independently associated with hypertension and cardiovascular disease <sup>67, 68</sup>, and 219 220 the role of SAS in the pathogenesis of hypertension in acromegaly should not be overlooked due to 221 its contribution to the flattening of the nocturnal BP fall.

#### 223 DIAGNOSIS AND MANAGEMENT

A recent consensus on the diagnosis and treatment of acromegaly complications <sup>31</sup> recommended an early diagnosis and aggressive treatment of high BP levels, regardless of the specific treatment of acromegaly. Therefore, BP measurement is always recommended at diagnosis of acromegaly, but it must be reassessed during the long-term follow-up (every 6 months, or when acromegaly treatment is changed, if hypertensive) <sup>31</sup>. It could be argued that the sole use of office measurements can lead to an overestimation of the frequency of hypertension <sup>24, 25</sup>, but this risk could be minimized using a self-measurement pressure diary or AMBP.

231 The choice of the antihypertensive agents, mainly angiotensin converting enzyme inhibitors 232 [ACEi], angiotensin II receptor blockers [ARBs], thiazide-type diuretics, calcium channel blockers, 233 does not significantly differ from the non-acromegalic patients and there is no recommendation on a preferential class of drugs <sup>31</sup>, although recent researches have suggested that amiloride is a 234 potentially interesting option <sup>36, 37</sup>. Moreover, a recent study including a small number of 235 236 acromegalic patients has demonstrated with cardiac magnetic resonance that cardiac indices were 237 improved in the hypertensive subjects on ACEi or ARBs compared with other antihypertensive drugs  $^{69}$ . Given that sleep apnea exacerbates hypertension  $^{68}$ , its effective management is mandatory 238 239 to improve BP control.

240

241

#### 242 EFFECT OF ACROMEGALY CONTROL

The effect of attaining control of GH and IGF1 excess on BP levels was heterogeneous across studies. In 2008, a study showed significantly lower systolic and diastolic BP levels in 76 acromegalic patients achieving disease control after 36 months, comparing with the remaining 29 uncontrolled patients. Moreover, increased doses, and/or greater number of antihypertensive drugs, were needed in patients with uncontrolled disease <sup>70</sup>. In addition, the biochemical control of acromegaly seems to have beneficial effects on BP levels also in non-hypertensive patients, preventing the progression towards hypertension  $^{33}$ . A recent study, including 121 acromegalic patients (of whom 79 achieving biochemical control during follow-up), confirmed that hypertension was more frequent in uncontrolled acromegaly  $^{20}$ .

252 However, some recently published articles downplayed the role of acromegaly control on BP levels. 253 A study including 552 acromegalic patients, stratified according to disease activity at the last visit, 254 demonstrated that the prevalence of hypertension was not modified by the successful treatment of acromegaly <sup>71</sup>. Previously, a research including 200 acromegalic patients did not demonstrated at 255 256 multivariate analysis that the lack of biochemical control was a predictor of hypertension, although 257 the univariate analysis showed a six-fold higher risk of hypertension in uncontrolled patients compared with patients in remission after surgery  $^{30}$ . Although the question is still open, we 258 259 reviewed a selection of papers addressing this issue that have been classified according to the treatment approach (Table 2). 260

261

### 262 SURGERY

263 The surgical removal of a GH-secreting adenoma, in most cases using a transsphenoidal approach, still represents the mainstay of treatment and a potentially rapid curative option <sup>72</sup>. Several studies 264 265 have investigated the impact of neurosurgery on BP levels and reported contrasting findings, 266 probably due to different sample sizes, type of measurements (clinical measurements versus 267 ABPM). BP cut-offs used, and timing of assessment after surgery. Studies showed a significant lowering of both clinical systolic and diastolic BP at 3<sup>73</sup> and 6 months after surgery <sup>74</sup>. The first 268 269 study used only office BP measurement, whereas ABPM was also performed in the second study 270 showing a significant postoperative decrease of the 24-h diurnal and nocturnal systolic BP profile with no change in the diastolic profile. Moreover, a circadian rhythm of BP was restored in most of 271 the patients with a blunted preoperative BP profile. Similarly, Minniti and colleagues <sup>75</sup>, using both 272 273 clinical measurement and ABPM before and 6 months after surgery, demonstrated a significant 274 decrease of the clinical and 24-h systolic BP in 15 well-controlled patients after surgery, in contrast

275 with no change in 15 poorly controlled acromegalic subjects. In the first group, a normal BP 276 circadian rhythm was restored in almost all patients, whereas no changes occurred in the second 277 group. The reduction in systolic, but not diastolic BP, 6 months after surgery was confirmed by Reves-Vidal and colleagues <sup>76</sup>; in addition, a lowered diastolic BP was found 1 year after surgery. 278 Colao and colleagues<sup>77</sup>, comparing 56 acromegalic patients controlled with SSA and 33 cured with 279 280 surgery, reported at 1 year a significant lowering of diastolic (but not systolic) BP in both groups. 281 Interestingly, the effect of a long-term effect of remission on diastolic BP was confirmed by a study reporting that after a mean period from surgery of 12.7 years diastolic (but not systolic) BP was 282 significantly lower in patients in remission than in patients with active acromegaly  $^{78}$ . 283

284

### 285 SOMATOSTATIN ANALOGUES

286 Although surgery is the treatment of choice, SSA (octreotide and lanreotide and the second-287 generation multireceptor-targeted pasireotide) are the first-line medical therapy, with a proved 288 efficacy in more than 50% of patients, and being able to improve significantly acromegalic comorbidities <sup>79, 80</sup>. A retrospective study comparing 36 acromegalics treated with SSA and 33 sex-, 289 290 age-, and BMI-matched patients cured after surgery, did not find any significant difference in diastolic and systolic BP between the two groups <sup>81</sup>. Previously, a prospective study showed a 291 292 significant reduction of systolic and diastolic BP in 36 acromegalic patients treated for 12-24months with depot long-acting octreotide <sup>82</sup>. In 2007, however, a metanalysis demonstrated that 293 294 SSA therapy did not lead to a clear fall in BP, suggesting a pressure-independent effect of SSA on heart <sup>83</sup>. In 2009, a study evaluated the efficacy of 5 years of depot SSA as first-line therapy in 295 acromegaly and demonstrated a reduction in BP and a reduction in the rate of hypertension <sup>84</sup>. 296

297

### 298 *PEGVISOMANT*

The second-line medical therapy consists of Pegvisomant (PEG), an antagonist of the GH receptor able to normalize IGF-1 levels in 60-90% of patients <sup>85-88</sup> and recently indicated as potentially responsible of permanent remission in selected patients with SSA-resistant acromegaly <sup>89</sup>. However,
 data on its impact on BP levels are limited to small size studies and are conflicting.

303 A prospective study including 16 patients with SSA-resistant acromegaly treated with PEG 304 demonstrated no change in systolic and diastolic BP overall; however, a significant decrease of diastolic BP was apparent in the 4 hypertensive patients evaluated separately <sup>90</sup>. Interestingly, 305 306 whereas a 6-month therapy with PEG in 17 acromegalic patients did not significantly change systolic and diastolic BP<sup>91</sup>, a 18-months therapy with PEG in 10 acromegalic patients significantly 307 308 lowered systolic BP in the entire group, as well as in the group of hypertensive patients, but decreased diastolic BP only in the hypertensive patients <sup>92</sup>. A recent prospective study of the same 309 310 group, including 50 acromegalic patients assessed at baseline, after long-term treatment with SSA 311 and after 12 and 60 months of combined treatment with SSA and PEG, demonstrated only a slight 312 but non-significant improvement of systolic and diastolic BP after combined treatment compared with long-term SSA therapy <sup>93</sup>. In 2010, Berg and colleagues <sup>94</sup> assessed BP levels at baseline and 313 314 after 12 months of PEG therapy in 62 acromegalic patients, of which 42 had normalized IGF-I 315 (controlled patients) and 20 had reduced, but not normalized IGF1 (partially controlled patients). 316 Systolic BP was significantly lower in the former than in the latter group, and decreased 317 significantly during treatment only in controlled patients, but not in partially controlled patients. 318 Diastolic BP was significantly lower in controlled than in partially controlled patients, but without significant changes in each group compared with baseline <sup>94</sup>. More recently, a retrospective study 319 320 including 96 patients treated with different modalities (surgery, SSA or PEG) reported a significant 321 reduction, among the 11 patients who were hypertensive at diagnosis and whose antihypertensive 322 treatment was not modified, in systolic BP after surgery, but not after PEG treatment, regardless of IGF1 changes <sup>95</sup>. 323

324

325 CABERGOLINE

326 Cabergoline is a dopamine agonist, used in acromegaly as an adjuvant treatment as monotherapy in

patients with mild disease or in combination with SSA <sup>72</sup>. To date, no prospective randomized trial
evaluating its efficacy in acromegaly is available and no study reporting its effect on hypertension
in acromegalic patients has been carried out.

330

#### 331 *RADIOTHERAPY*

Radiotherapy is currently considered as a third-line option, in acromegalic patients uncontrolled after surgery and medical therapy, or in case of aggressive GH-secreting tumors <sup>72</sup>. To our knowledge, no data focusing on the effect of radiotherapy on hypertension in acromegalic patients has been reported.

336

#### 337 CONCLUSION

Hypertension is one of the most important and common complications in acromegaly. Its pathogenesis has not yet been fully elucidated, and likely includes multiple factors. A comprehensive, patient-centered approach, focusing not only on the biochemical control of acromegaly, but also on an early diagnosis of hypertension and a prompt anti-hypertensive treatment, is required for optimal patient care. However, there is an urgent need of prospective, large-scale studies focusing on hypertension, and its response to treatment of acromegaly, to solve the conundrum whether control of GH-IGF1 excess ameliorates BP levels.

#### 345 **REFERENCES**

- **1.** Melmed S. Acromegaly. N Engl J Med 1990; 322:966-77.
- 2. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology,
  pathogenesis, and management. Endocr Rev 2004; 25:102-52.
- 349 3. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome,
- 350 morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro
- Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439-46.
- 4. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin
  Endocrinol Metab 2004; 89:667–674.
- 354 5. Holdaway IM, Bolland MJ, Gamble GD. A metanalysis of the effect of lowering serum levels of
- GH and IGF-1 on mortality in acromegaly. Eur. J. Endocrinol. 2008; 159: 89–95.
- **6.** Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly:
- an Italian survey. Eur J Endocrinol. 2012; 167:189-98.
- 358 7. Ragonese M, Alibrandi A, Di Bella G, et al. Cardiovascular events in acromegaly: distinct role of
- Agatston and Framingham score in the 5-year prediction. Endocrine. 2014; 47:206-12.
- 360 8. López-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly:
- 361 specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab. 1997;
  362 82:1047-53.
- 363 9. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are
  364 independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol
  365 Metab 2000; 85:193–199.
- 366 10. Mercado M, Gonzalez B, Vargas G, et al. Successful mortality reduction and control of
- 367 comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
- 368 J Clin Endocrinol Metab 2014; 99:4438–4446.
- 369 11. Ritvonen E, Löyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up
- 370 study. Endocr Relat Cancer 2015; 23:469–480.

- **12.** Broder MS, Neary MP, Chang E, et al. Treatments, complications, and healthcare utilization
  associated with acromegaly: a study in two large United States databases. Pituitary 2014; 17: 333–
  341.
- **13.** Bex M, Abs R, T'Sjoen G, et al. AcroBel the Belgian registry on acromegaly: a survey of the
  'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007;157:399-409.
- **14.** Anagnostis P, Efstathiadou ZA, Polyzos SA, et al. Acromegaly: presentation, morbidity and
  treatment outcomes at a single centre. Int J Clin Pract. 2011; 65:896-902.
- 378 15. Mercieca C, Gruppetta M, Vassallo J. Epidemiology, treatment trends and outcomes of
  acromegaly. Eur J Intern Med. 2012; 23:e206-7.
- 380 **16.** Vallette S, Ezzat S, Chik C, et al. Emerging trends in the diagnosis and treatment of acromegaly
- 381 in Canada. Clin Endocrinol (Oxf). 2013; 79:79-85.
- 17. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of
  acromegaly, a nationwide study from 1955 through 2013. Pituitary. 2015; 18:803-7.
- **18.** Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications
- and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016; 175:181-90.
- 386 **19.** Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, et al. The Mexican Acromegaly
- 387 Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes. J Clin
- 388 Endocrinol Metab. 2016; 101:3997-4004.
- **20.** Carmichael JD, Broder MS, Cherepanov D, et al. Long-term treatment outcomes of acromegaly
- patients presenting biochemically-uncontrolled at a tertiary pituitary center. BMC Endocr Disord.
  2017; 17:49.
- 21. Lesén E, Granfeldt D, Houchard A, et al. Comorbidities, treatment patterns and cost-of-illness
  of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017;
  176:203-212.
- 395 22. Schofl C, Petroff D, Tonjes A, et al. Incidence of myocardial infarction and stroke in
  396 acromegaly patients: results from the German Acromegaly Registry. Pituitary. 2017; 20:635-42.

- 397 23. Maione L, Brue T, Beckers A, et al. Changes in the management and comorbidities of
  acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017; 176:64555.
- 400 24. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertension in acromegalic
  401 patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin
  402 Endocrinol (Oxf). 1998; 48:149–152.
- **25.** Costenaro F, Martin A, Horn RF, et al. Role of ambulatory blood pressure monitoring in
  patients with acromegaly. J Hypertens. 2016; 34:1357–1363.
- 405 26. Ohtsuka H, Komiya I, Aizawa T, et al. Hypertension in acromegaly: hereditary hypertensive
- 406 factor produces hypertension by enhancing IGF-I production. Endocr J. 1995; 42:781–787.
- 407 27. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal
  408 population: prevalence and determinants. Clin Endocrinol (Oxf). 2005; 63:470–476.
- 28. Schutte AE, Volpe M, Tocci G, et al. Revisiting the relationship between blood pressure and
  insulin-like growth factor-1. Hypertension 2014; 63:1070–1077.
- **29.** Powlson AS, Gurnell M. Cardiovascular disease and sleep disordered breathing in acromegaly.
  Neuroendocrinology 2016; 103:75–85.
- 413 **30.** Sardella C, Cappellani D, Urbani C, et al. Disease activity and lifestyle influence comorbidities
- and cardiovascular events in patients with acromegaly. Eur J Endocrinol. 2016;175(5): 443–453.
- 415 **31.** Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of
  416 acromegaly complications Pituitary. 2013; 16:294-302.
- 417 **32.** Terzolo M, Matrella C, Boccuzzi A, et al. Twenty-four hour profile of blood pressure in patients
- with acromegaly. Correlation with demographic, clinical and hormonal features. J EndocrinolInvest. 1999; 22:48–54.
- 420 **33.** Sardella C, Urbani C, Lombardi M, et al. The beneficial effect of acromegaly control on blood
- 421 pressure values in normotensive patients. Clin. Endocrinol 2014; 81: 573–581.
- 422 34. Feld S, Hirschgerg R. Growth Hormone, the insulin-like growth factor system, and the kidney. J

- 423 Clin Endocrinol Metab 1996; 5:423–480
- 424 35. Lin CJ, Mendonca BB, Lucon AM, et al. Growth hormone receptor messenger ribonucleic acid
  425 in normal and pathologic human adrenocortical tissues—An analysis by quantitative polymerase
  426 chain reaction technique. J Clin Endocrinol Metab 1997; 82:2671–2676.
- 427 36. Kamenicky P, S. Viengchareun, A. Blanchard, et al. Epithelial sodium channel is a key
  428 mediator of growth hormone induced sodium retention in acromegaly. Endocrinology. 2008; 149:
  429 3294–3305.
- 430 37. Kamenicky P, A. Blanchard, M. Frank, S. et al. Body fluid expansion in acromegaly is related
  431 to enhanced epithelial sodium channel (ENaC) activity. J. Clin. Endocrinol. Metab. 2011; 96:2127–
  432 2135.
- 38. Bielohuby M, Roemmler J, Manolopoulou J, et al. Chronic growth hormone excess is associated
  with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic
  mice. Exp Biol Med (Maywood). 2009; 234:1002–1009.
- **39.** Moller J, Jorgensen JO, Marqversen J, et al. Insulin-like growth factor I administration induces
- 437 fluid and sodium retention in healthy adults: Possible involvement of renin and atrial natriuretic
- 438 factor. Clin Endocrinol (Oxf) 2000;52:181–186.
- 439 40. Kraatz C, Benker G, Weber F, et al. Acromegaly and hypertension: Prevalence and relationship
  440 to the renin-angiotensin-aldosterone system. Klin Wochenschr 1990; 68:583–587.
- 441 41. Zacharieva S, Andreeva M, Andonova K. Effect of sodium depletion on the renin-angiotensin-
- aldosterone system and renal prostaglandins in acromegalic patients. Exp Clin Endocrinol. 1990;
  96:213-8.
- 42. Mulatero P, Veglio F, Maffei P, et al. CYP11B2-344T/C Gene Polymorphism and Blood
  Pressure in Patients with Acromegaly. J Clin Endocrinol Metab. 2006; 91:5008-12.
- 446 43. Erbas T, Cinar N, Dagdelen S, et al. Association between ACE and AGT polymorphism and
- 447 cardiovascular risk in acromegalic patients. Pituitary. 2017; 20:569-577.
- 448 44. McKnight JA, McCance DR, Hadden DR, et al. Basal and saline-stimulated levels of plasma

- atrial natriuretic factor in acromegaly. Clin Endocrinol 1989; 31:431–438.
- 450 **45.** Brands MW, Manhiani MM. Sodium-retaining effect of insulin in diabetes. Am J Physiol Regul
- 451 Integr Comp Physiol. 2012; 303:R1101-9.
- 452 **46.** Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, et al. High blood pressure and 453 hyperinsulinaemia in acromegaly and in obesity. Clin Exp Hypertens 1989;A11:407–425.
- 454 **47.** Ikeda T, Terasawa H, Ishimura M, et al. Correlation between blood pressure and plasma insulin
- 455 in acromegaly. J Int Med 1993; 234:61–63.
- 456 48. Ezzat S, Forster MJ, Berchtold P, et al. Acromeglay. Clinical and biochemical features in 500
- 457 patients. Medicine (Baltimore) 1994; 73:233–240.
- 458 49. Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose
- tolerance in acromegaly. Clin Endocrinol (Oxf) 2001;54:189–195.
- 460 **50.** Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in
  461 acromegaly. Pituitary. 2001; 4: 239–249.
- 462 **51.** Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension.
  463 Circ Res. 2015; 116:976-90.
- 464 **52.** Bondanelli M, Ambrosio MR, Franceschetti P, et al. Diurnal rhythm of plasma catecholamines
  465 in acromegaly. J Clin Endocrinol Metab 1999; 84:2458-67.
- 466 **53.** Sumbul HE, Koc AS. Hypertension is Common in Patients with Newly Diagnosed Acromegaly
- and is Independently Associated with Renal Resistive Index. High Blood Press Cardiovasc Prev.
  2019; 26:69-75.
- 469 54. Kamide K, Hori MT, Zhu JH, et al. Insulin and insulin-like growth factor-I promotes
  470 angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000;
  471 18:1051–1056.
- 472 **55.** Rizzoni D, Porteri E, Giustina A, et al. Acromegalic patients show the presence of 473 hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension. 2004; 43:561–
- 474 565.

- 56. Paisley AN, Izzard AS, Gemmell I, et al. Small vessel remodeling and impaired endothelialdependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin
  Endocrinol Metab. 2009; 94:1111-7.
- 478 57. Maison P, Démolis P, Young J, et al. Vascular reactivity in acromegalic patients: preliminary
  479 evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin
  480 Endocrinol (Oxf). 2000; 53:445-51.
- 481 58. Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly:
  482 cardiovascular implications. Blood Press. 2005; 14:227-32.
- 483 **59.** Baykan M, Erem C, Gedikli O, et al. Impairment in flow-mediated vasodilatation of the brachial
  484 artery in acromegaly. Med Princ Pract. 2009;18:228-32.
- 485 60. Yaron M, Izkhakov E, Sack J, et al. Arterial properties in acromegaly: relation to disease
  486 activity and associated cardiovascular risk factors. Pituitary. 2016; 19:322-31.
- 487 61. Anagnostis P, Efstathiadou ZA, Gougoura S, et al. Oxidative stress and reduced antioxidative
  488 status, along with endothelial dysfunction in acromegaly. Horm Metab Res. 2013; 45:314-8.
- 489 62. Chen Z, Yu Y, He M, et al. HIGHER GROWTH HORMONE LEVELS ARE ASSOCIATED
- 490 WITH ERECTILE DYSFUNCTION IN MALE PATIENTS WITH ACROMEGALY. Endocr
- 491 Pract. 2019 Mar 13.
- 63. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to
  cardiovascular diseases. Diabetes Metab Res Rev. 2006; 22:423-36.
- 64. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadian blood pressure profile in
  patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J
  Hum Hypertens 2001; 15:601–605.
- 497 65. Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab.
  498 2010; 95:483–495.
- 66. Davì MV, Giustina A. Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects
  and treatment. Expert Rev Endocrinol Metab. 2012; 7:55-62.

- 501 **67.** Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for 502 hypertension: Population study. BMJ 2000;320:479–482.
- 503 68. Bradley TD, Floras JS: Obstructive sleep apnoea and its cardiovascular consequences. Lancet
  504 2009; 373: 82–93.
- 505 69. Thomas JDJ, Dattani A, Zemrak F, et al. Renin-Angiotensin System Blockade Improves
- 506 Cardiac Indices in Acromegaly Patients. Exp Clin Endocrinol Diabetes. 2017; 125:365-367.
- 507 70. Colao A, Terzolo M, Bondanelli M, et al. GH and IGF-I excess control contributes to blood
- 508 pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive
- acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf). 2008; 69:613-20.
- 510 **71.** González B, Vargas G, de Los Monteros ALE, et al. Persistence of Diabetes and Hypertension
- 511 After Multimodal Treatment of Acromegaly. J Clin Endocrinol Metab. 2018; 103:2369-2375.
- 512 72. Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society. Acromegaly: an endocrine
  513 society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99:3933-51.
- 73. Yonenaga M, Fujio S, Habu M, et al. Postoperative Changes in Metabolic Parameters of
  Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure
  Criteria.Neurol Med Chir (Tokyo). 2018; 58:147-155.
- 517 74. Jaffrain-Rea ML, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on
  518 cardiovascular risk factors in acromegaly Eur J Endocrinol. 2003; 148:193-201.
- 519 75. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function
  520 after successful transsphenoidal surgery in acromegalic patients Clin Endocrinol (Oxf). 2001;
  55:307-13.
- 76. Reyes-Vidal C, Fernandez JC, Bruce JN, et al. Prospective study of surgical treatment of
  acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab.
  2014; 99:4124-32.
- 525 77. Colao A, Pivonello R, Galderisi M, et al. Impact of Treating Acromegaly First with Surgery or
- 526 Somatostatin Analogs on Cardiomyopathy J Clin Endocrinol Metab. 2008; 93:2639-46.

- 527 **78.** Serri O, Beauregard C, Hardy J. Long-Term Biochemical Status and Disease-Related Morbidity
- 528 in 53 Postoperative Patients with Acromegaly. J Clin Endocrinol Metab. 2004; 89:658-61.
- 529 79. Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly Clinical Trial Methodology Impact on
- 530 Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-
- 531 Analysis. J. Clin. Endocrinol. Metab. 2014; 99: 1825-33.
- **80.** Gadelha MR, Bronstein MD, Brue T et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2: 875-84.
- 81. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with longacting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk
  factors. J Clin Endocrinol Metab. 2006; 91:121-8.
- 82. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin
  analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab.
  2001; 86:2779-86.
- 83. Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in
  acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007; 92:1743-7.
- 543 84. Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with
  somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels,
  tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;
  94:3746–3756.
- 547 **85.** Trainer P, Drake W, Katznelson L et al. Treatment of acromegaly with the growth hormone548 receptor antagonist pegvisomant. N. Engl. J. Med. 2000; 342:1171–1177.
- 549 86. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with
  550 pegvisomant, a growth hormone receptor antagonist. Lancet. 2001; 358:1754–59.
- **87.** Grottoli S, Maffei P, Bogazzi F et al, ACROSTUDY: the Italian experience. Endocrine. 2015;
  48: 334-41.

- 88. Ragonese M, Grottoli S, Maffei P et al. How to improve effectiveness of pegvisomant treatment
  in acromegalic patients. J. Endocrinol. Invest. 2017; 41:575-581.
- 89. Puglisi S, Spagnolo F, Ragonese M, et al. First report on persistent remission of acromegaly
  after withdrawal of long-term pegvisomant monotherapy. Growth Horm IGF Res. 2019; 45:17-19.
- **90.** Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance Eur J Endocrinol. 2006; 154:467-77.
- 91. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with Growth Hormone Receptor
  Antagonist in Acromegaly: Effect on Cardiac Structure and Performance. J Clin Endocrinol Metab.
  2007; 92:476-82.
- 564 92. De Martino MC, Auriemma RS, Brevetti G, et al. The treatment with growth hormone receptor
  565 antagonist in acromegaly: effect on vascular structure and function in patients resistant to
  566 somatostatin analogues. J Endocrinol Invest. 2010; 33:663-70.
- 93. Auriemma RS, Grasso LF, Galdiero M, et al. Effects of long-term combined treatment with
  somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.
  Endocrine. 2017; 55:872-884.
- 94. Berg C, Petersenn S, Lahner H, et al. Cardiovascular risk factors in patients with uncontrolled
  and long-term acromegaly: comparison with matched data from the general population and the
  effect of disease control. J Clin Endocrinol Metab. 2010; 95:3648-56.
- 573 95. Briet C, Ilie MD, Kuhn E, et al. Changes in metabolic parameters and cardiovascular risk
  574 factors after therapeutic control of acromegaly vary with the treatment modality. Data from the
  575 Bicêtre cohort, and review of the literature. Endocrine. 2019; 63:348-360.
- 576
- 577
- 578

Country	No of	No of HTN	% of HTN	Mean	Study	Year of	References
	patients <sup>*</sup>	patients	patients <sup>#</sup>	age	period	publication	
Spain	1036	405	39.1	45.0	1997 – 2003	2004	[3]
New Zealand	126	69	54.7	42.0	1964 – 2000	2004	[4]
Belgium	409	161	39.4	44.0	2000 - 2004	2007	[13]
Greece	84	-	46.0	47.0	1980 – 2009	2011	[14]
Italy	1512	-	33.0	45.0	1980 - 2002	2012	[6]
Malta	47	22	46.8	43.4	1979 – 2008	2012	[15]
Canada	537	198	36.9	45.0	1980 – 2010	2013	[16]
Iceland	52	25	48.1	44.5	1955 – 2013	2015	[17]
Denmark	405	44	11.0	48.7	1991 – 2010	2016	[18]
Mexico	2057	-	27.0	41.0	2009	2016	[19]
USA	120	57	47.5	55.4	1985 – 2013	2017	[20]
Sweden	358	142	39.7	50.0	2005 - 2013	2017	[21]
Germany	479	186	45.5	45.7	2016	2017	[22]
France	947	-	33.0	46.0	1999 – 2012	2017	[23]
Weighted mea	ın		33.6				
Range			11.0-54.7				

579 Table 1 – Frequency of hypertension (HTN) in acromegaly in studies published over the last 15 years
580 [national or local registries of acromegalic patients].

581 \**if specified, only patients with known information about hypertension;* 

582 <sup>#</sup>*if specified, data at diagnosis.* 

**Table 2** – Effects of different treatments of acromegaly on hypertension.

TREATMENT	EFFECT ON HTN	REFERENCES				
Surgery	Amelioration of HTN with	[73-78]				
	conflicting data on a more					
	prominent effect on SBP vs. DBP					
Somatostatin analogues	Possible amelioration of HTN	[81-84]				
	with long-term control of					
	acromegaly					
Pegvisomant	Amelioration of HTN with long-	[90-95]				
	term control of acromegaly					
Cabergoline	NA	-				
Radiotherapy	NA	-				
<b>Abbreviations are as fo</b>	Abbreviations are as follows: HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic					
0 blood pressure; NA, no	blood pressure; NA, not available					
1						
2						
<b>FIGURE LEGEND</b>	FIGURE LEGEND					
1						
<b>Fig 1. Pathogenesis of h</b>	Fig 1. Pathogenesis of hypertension in acromegaly.					